Drug Industry Rips Into FDA Over Social Media Guidelines A Summary of Industry Comments Regarding Twitter & Google Adwords
Ever since the epic #FAIL of FDA’s July 10, 2014 webinar, which attempted to explain the agency’s June 2014 social media guidelines, FDA has been the butt of jokes on pundit blogs (e.g., Pharma Marketing Blog) and also behind “closed doors” at industry conferences. In particular, the agency was criticized for not being technically savvy enough to understand the nuances of social media and search engine advertising.
Now, the industry’s door is open thanks to comments recently submitted to the docket by industry groups and made public by the FDA. It’s always interesting and educational to read these comments.
This article summarizes some of the main points made by PhRMA, Washington Legal Foundation (WLF), BIO, Medical Information Working Group (MIWG), Patient, Consumer, and Public Health Coalition, and several pharmaceutical companies, regarding FDA’s Draft Guidance on using Internet and social media platforms with character space limitations.
Topics include (partial list):
- FDA is Inconsistent, Says PhRMA
- What’s Good for the Goose (FDA) Should Be Good for the Gander (Pharma)
- Fist Amendment Issues
- FDA Rules are Anti-“Patient-Centric”
- PhRMA Recommends the “One-Click Rule”
- FDA’s Poorly Defined New Media Landscape
Download the full text PDF file here:
Issue: Vol. 13, No. 8: September 2014